Omalizumab
- Generic Name
- Omalizumab
- Brand Names
- Xolair, Omlyclo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 242138-07-4
- Unique Ingredient Identifier
- 2P471X1Z11
- Background
Omalizumab, manufactured by Genentech, was first FDA approved in 2003 to treat adults and children 12 years of age and older with moderate to severe persistent allergic asthma which is not controlled by inhaled steroids . Since its U.S. approval, more than 200,000 patients older than 12 with allergic asthma have been treated . In September 2018, a new prefil...
- Indication
This drug is an anti-IgE antibody indicated for:
- Associated Conditions
- Chronic Idiopathic Urticaria, Moderate Asthma, Severe Asthma
- Associated Therapies
- -
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-10-25
- Lead Sponsor
- Novartis
- Target Recruit Count
- 133
- Registration Number
- NCT00219323
- Locations
- 🇯🇵
This study is not being conducted in the United States, Tokyo, Japan
Effect of Xolair on Airway Hyperresponsiveness
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2011-09-23
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 22
- Registration Number
- NCT00208234
- Locations
- 🇺🇸
Creighton University Division of Allergy & Immunology, Omaha, Nebraska, United States
Efficacy of Omalizumab as Add on Therapy for Minority Patients With Moderate to Severe Asthma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2012-02-28
- Lead Sponsor
- DiMango, Emily, M.D.
- Target Recruit Count
- 18
- Registration Number
- NCT00180011
- Locations
- 🇺🇸
Columbia University, New York, New York, United States
Effect of Anti-IgE in Non-Allergic Asthma
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 29
- Registration Number
- NCT00162773
- Locations
- 🇺🇸
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States
The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma
- Conditions
- First Posted Date
- 2005-08-22
- Last Posted Date
- 2011-09-20
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 16
- Registration Number
- NCT00133042
- Locations
- 🇺🇸
University of Florida Asthma Research Lab, Gainesville, Florida, United States
A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab
- First Posted Date
- 2005-07-25
- Last Posted Date
- 2016-05-20
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 30
- Registration Number
- NCT00123630
- Locations
- 🇺🇸
University of Utah HSC, Salt Lake City, Utah, United States
Omalizumab to Treat Eosinophilic Gastroenteritis
- Conditions
- First Posted Date
- 2004-06-07
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 30
- Registration Number
- NCT00084097
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma
- First Posted Date
- 2004-03-22
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 628
- Registration Number
- NCT00079937
- Locations
- 🇺🇸
Clinical Research Institute of Southern Oregon, Medford, Oregon, United States
🇺🇸Family Allergy and Asthma Center, PC, Atlanta, Georgia, United States
🇺🇸West Penn Allegheny General Health System, Pittsburgh, Pennsylvania, United States
Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma
- Conditions
- First Posted Date
- 2002-10-04
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 484
- Registration Number
- NCT00046748
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.